Azithromycin-loaded respirable microparticles for targeted pulmonary delivery for the treatment of pneumonia
Related Experiment Video
Updated: Feb 14, 2026
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
Qiyue Wang1, Gujie Mi2, Daniel Hickey2
1Center for Research Development and Evaluation of Pharmaceutical Excipients and Generic Drugs, Department of Pharmaceutics, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, China.
Abstract:
Pneumonia is a major contributor to infection-based hospitalizations and deaths in the United States. Antibiotics such as azithromycin (AZM), although effective at managing pneumonia, often suffer from off-target diffusion and poor bioavailability when administered orally or via intravenous injection. The formation of biofilms at the disease sites makes the treatment more complicated by protecting bacteria from antimicrobial agents and thus necessitating a much higher dosage of antibiotics to eradicate the biofilms. As such, targeted pulmonary delivery of antibiotics has emerged as a promising alternative by providing direct access to the lung while also allowing higher local therapeutic concentrations but minimal systemic exposure. In this study, AZM was encapsulated in N-fumaroylated diketopiperazine (FDKP) microparticles for efficient pulmonary delivery. Both in vitro and in vivo results demonstrated that AZM@FDKP-MPs administered via intratracheal insufflation achieved at least a 3.4 times higher local concentration and prolonged retention times compared to intravenous injection and oral administration, suggesting their potential to better manage bacterial pneumonia.
Insights
Targeted delivery of azithromycin (AZM) in N-fumaroylated diketopiperazine (FDKP) microparticles enhances pneumonia treatment. This method achieves higher lung concentrations and longer retention than traditional antibiotic delivery methods.
Area of Science:
- Pulmonary Drug Delivery
- Nanomedicine
- Infectious Diseases
Background:
- Pneumonia is a significant cause of hospitalization and mortality in the US.
- Current azithromycin (AZM) delivery methods (oral, IV) have limitations like poor bioavailability and off-target effects.
- Bacterial biofilms complicate pneumonia treatment, requiring higher antibiotic doses.
Purpose of the Study:
- To develop and evaluate N-fumaroylated diketopiperazine (FDKP) microparticles for targeted pulmonary delivery of azithromycin (AZM).
- To compare the efficacy of intratracheal AZM@FDKP-MPs with conventional AZM administration routes.
Main Methods:
- Azithromycin (AZM) was encapsulated within N-fumaroylated diketopiperazine (FDKP) microparticles (MPs).
- AZM@FDKP-MPs were administered via intratracheal insufflation in preclinical models.
- In vitro and in vivo studies assessed drug concentration, retention time, and efficacy.
Main Results:
- Intratracheal administration of AZM@FDKP-MPs resulted in a 3.4-fold higher local drug concentration in the lungs compared to IV or oral routes.
- Prolonged drug retention times were observed with pulmonary delivery.
- The targeted delivery approach showed potential for improved pneumonia management.
Conclusions:
- N-fumaroylated diketopiperazine (FDKP) microparticles enable efficient targeted pulmonary delivery of azithromycin (AZM).
- Intratracheal insufflation of AZM@FDKP-MPs offers superior local drug concentration and retention for pneumonia treatment.
- This novel delivery system presents a promising strategy to overcome limitations of conventional antibiotic administration for bacterial pneumonia.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:24Respiration
Energy production in the human body is primarily fueled by oxidation, a process where food molecules are burned by combining with oxygen to produce carbon dioxide and water. This vital metabolic process sustains life, and is supported intricately by the respiratory system.
Structure and Function of the Respiratory System:
The respiratory system is a complex network of structures that includes the nose, oropharynx, larynx, trachea,...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...